Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Analysts have set a 1-year consensus target price of $115.00 for the company and are forecasting that the company will post $2.26 EPS for the current quarter, according to Zacks. Zacks has also given Taro Pharmaceutical Industries an industry rank of 39 out of 255 based on the ratings given to related companies.

A number of research analysts recently issued reports on the company. Zacks Investment Research lowered Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. TheStreet upgraded Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a report on Friday, February 15th. Finally, ValuEngine upgraded Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Thursday, January 10th.

A number of institutional investors have recently bought and sold shares of the business. First Manhattan Co. acquired a new position in Taro Pharmaceutical Industries in the 1st quarter valued at about $3,810,000. Geode Capital Management LLC boosted its holdings in Taro Pharmaceutical Industries by 124.1% in the 4th quarter. Geode Capital Management LLC now owns 7,255 shares of the company’s stock valued at $613,000 after purchasing an additional 4,018 shares in the last quarter. Norges Bank purchased a new stake in Taro Pharmaceutical Industries in the 4th quarter valued at approximately $20,825,000. Actinver Wealth Management Inc. purchased a new stake in Taro Pharmaceutical Industries in the 4th quarter valued at approximately $2,409,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Taro Pharmaceutical Industries by 11.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 300,981 shares of the company’s stock valued at $25,476,000 after purchasing an additional 31,555 shares in the last quarter. Institutional investors own 10.07% of the company’s stock.

NYSE:TARO opened at $103.91 on Tuesday. The firm has a market capitalization of $4.10 billion, a P/E ratio of 16.81 and a beta of 0.53. Taro Pharmaceutical Industries has a 12-month low of $76.93 and a 12-month high of $121.23.

Taro Pharmaceutical Industries (NYSE:TARO) last released its earnings results on Wednesday, February 6th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.45. The firm had revenue of $176.38 million during the quarter, compared to analyst estimates of $174.70 million. Taro Pharmaceutical Industries had a return on equity of 14.27% and a net margin of 46.55%. As a group, research analysts anticipate that Taro Pharmaceutical Industries will post 7.97 EPS for the current year.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Recommended Story: What are the benefits of investing in REITs?

Get a free copy of the Zacks research report on Taro Pharmaceutical Industries (TARO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.